

Special Issue

Liver Resection and Liver Transplantation for Hepatocellular Carcinoma

Message from the Guest Editor

This Special Issue focuses on the surgical treatment of hepatocellular carcinoma (HCC), including liver resection and liver transplantation. The development of effective systemic therapies, such as molecular target agents and immunotherapy, has revolutionized the treatment of unresectable/untransplantable HCC and improved survival outcomes. Additionally, some groups have reported excellent outcomes with updated transarterial chemotherapy for primarily unresectable HCC. Surgical treatment has also been rapidly evolving with the incorporation of effective preoperative and postoperative treatments, known as neoadjuvant, conversion, bridging, and others. To date, the terminology for these combined treatment strategies has not been clearly defined, nor has their effectiveness been firmly established. In this Special Issue, we welcome papers that address the concepts, trials, outcomes, and perspectives of modern surgical strategies for HCC, which aim to make liver resection and liver transplantation more effective and widely applicable.

Guest Editor

Dr. Satoshi Ogiso

Division of Hepato-Biliary-Pancreatic Surgery and Transplantation,
Department of Surgery, Graduate School of Medicine, Kyoto University,
Kyoto 602-0841, Japan

Deadline for manuscript submissions

closed (25 July 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/211995

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)